OQS
ENTA icon

Occudo Quantitative Strategies’s Enanta Pharmaceuticals ENTA Stock Holding History

Occudo Quantitative Strategies’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,549
Closed -$186K – 749
2025
Q3 		$186K Buy
+15,549
New +$124K 0.02% 589
2024
Q1 		– Sell
-29,641
Closed -$279K – 817
2023
Q4 		$279K Buy
29,641
+5,388
+22% +$50.2K 0.04% 556
2023
Q3 		$271K Buy
+24,253
New +$391K 0.04% 702

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Occudo Quantitative Strategies's ENTA Position: Q4 2025 in Review

Occudo Quantitative Strategies sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 15,549 shares — an estimated $186K sold.

Occudo Quantitative Strategies first reported a position in ENTA in Q3 2023 and held it in 3 quarters. The position peaked at $279K in Q4 2023. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Occudo Quantitative Strategies reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 15,549 Enanta Pharmaceuticals shares in Q4 2025, an estimated $186K.
  • Occudo Quantitative Strategies first reported a position in Enanta Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Enanta Pharmaceuticals position peaked at $279K in Q4 2023.
  • 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.